OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer
Yang Peng, Haochen Yu, Yudi Jin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 14
Yang Peng, Haochen Yu, Yudi Jin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 14
Showing 14 citing articles:
GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway
Weidan Zhang, Xin Tang, Yang Peng, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 4
Open Access | Times Cited: 7
Weidan Zhang, Xin Tang, Yang Peng, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 4
Open Access | Times Cited: 7
Research progress on immunotherapy in triple‑negative breast cancer (Review)
Xiaoxiao Zhang, Xueying Ge, Tinghan Jiang, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 2
Open Access | Times Cited: 19
Xiaoxiao Zhang, Xueying Ge, Tinghan Jiang, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 2
Open Access | Times Cited: 19
An original cuproptosis-related genes signature effectively influences the prognosis and immune status of head and neck squamous cell carcinoma
Xiwang Zheng, Chunming Zhang, Defei Zheng, et al.
Frontiers in Genetics (2023) Vol. 13
Open Access | Times Cited: 12
Xiwang Zheng, Chunming Zhang, Defei Zheng, et al.
Frontiers in Genetics (2023) Vol. 13
Open Access | Times Cited: 12
A Clinical–Radiomics Model for Predicting Axillary Pathologic Complete Response in Breast Cancer With Axillary Lymph Node Metastases
Liangyu Gan, Mingming Ma, Yinhua Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 22
Liangyu Gan, Mingming Ma, Yinhua Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 22
LncRNA HOTAIR as a ceRNA is related to breast cancer risk and prognosis
Liyu Qian, Li Li, Yang Li, et al.
Breast Cancer Research and Treatment (2023) Vol. 200, Iss. 3, pp. 375-390
Closed Access | Times Cited: 8
Liyu Qian, Li Li, Yang Li, et al.
Breast Cancer Research and Treatment (2023) Vol. 200, Iss. 3, pp. 375-390
Closed Access | Times Cited: 8
PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer
Xueting Ren, Hanxiao Cui, Luyao Dai, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 3
Open Access | Times Cited: 2
Xueting Ren, Hanxiao Cui, Luyao Dai, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 3
Open Access | Times Cited: 2
GLDADec: marker-gene guided LDA modeling for bulk gene expression deconvolution
Iori Azuma, Tadahaya Mizuno, Hiroyuki Kusuhara
Briefings in Bioinformatics (2024) Vol. 25, Iss. 4
Open Access | Times Cited: 2
Iori Azuma, Tadahaya Mizuno, Hiroyuki Kusuhara
Briefings in Bioinformatics (2024) Vol. 25, Iss. 4
Open Access | Times Cited: 2
Breast Cancer Prognosis Prediction and Immune Pathway Molecular Analysis Based on Mitochondria-Related Genes
Weixu Luo, Yuanshan Han, Xin Li, et al.
Genetics Research (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 10
Weixu Luo, Yuanshan Han, Xin Li, et al.
Genetics Research (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 10
Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer
Xin Jin, Yan Junfeng, Chuanzhi Chen, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 7
Xin Jin, Yan Junfeng, Chuanzhi Chen, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 7
Development and validation of a prediction model for the diagnosis of breast cancer based on clinical and ultrasonic features
Xuan He, Yuanyuan Lu, Junlai Li
Gland Surgery (2023) Vol. 12, Iss. 6, pp. 736-748
Open Access | Times Cited: 2
Xuan He, Yuanyuan Lu, Junlai Li
Gland Surgery (2023) Vol. 12, Iss. 6, pp. 736-748
Open Access | Times Cited: 2
Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients
Jian Wan, Shizhen Chen, Anqin Zhang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 3
Jian Wan, Shizhen Chen, Anqin Zhang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 3
GLDADec: marker-gene guided LDA modelling for bulk gene expression deconvolution
Iori Azuma, Tadahaya Mizuno, Hiroyuki Kusuhara
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Iori Azuma, Tadahaya Mizuno, Hiroyuki Kusuhara
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Clinical Significance, Immune Landscape and Immunotherapy Efficacy Analyses of Cuproptosis-Tumor Immunological Phenotype-Related Gene Score Based Prognostic Model in Breast Cancer
Fengyuan Hu, Junyang Wang, YanKe Chen, et al.
Research Square (Research Square) (2024)
Open Access
Fengyuan Hu, Junyang Wang, YanKe Chen, et al.
Research Square (Research Square) (2024)
Open Access
Development and Validation of a 7-Gene Inflammatory Signature Forecasts Prognosis and Diverse Immune Landscape in Lung Adenocarcinoma
Aitao Nai, Feng Ma, Zirui He, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 2
Aitao Nai, Feng Ma, Zirui He, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 2
